One-year outcomes of Bent ab-interno needle goniectomy with phacoemulsification in primary glaucoma

原发性青光眼行弯曲内切针房角切除联合超声乳化术的一年疗效

阅读:2

Abstract

PURPOSE: To study 1-year outcomes of bent ab-interno needle goniectomy (BANG) with phacoemulsification in patients across the glaucoma spectrum. METHODS: This Prospective, noncomparative interventional study enrolled primary glaucoma patients (open-angle and angle-closure) with medically controlled intraocular pressure (IOP) and visually significant cataracts who underwent clear corneal phacoemulsification with intraocular lens placement combined with BANG using a 25-gauge needle bent as a reverse cystitome. Patients completing a minimum 1-year post-surgical follow-up were analyzed. The primary outcome was the change in antiglaucoma medications (AGM) required after surgery. Complete and qualified success was defined as IOP between 6 and 21 mm Hg without and with up to two topical AGMs. RESULTS: Thirty eyes of 30 patients with a mean age of 60.5 ± 10.3 years were analyzed. The mean baseline IOP was 15.3 ± 3.6 mmHg, and the mean number of topical AGM was 2.6 ± 1.3. Ten patients were on systemic acetazolamide. The topical AGM requirement decreased to 0.60 ± 0.99 (P < 0.0001) and 0.87 ± 1.02 (P < 0.0001) at 6 months and 1 year, respectively. The mean IOP decreased to 13.57 ± 2.79 (P = 0.028) and 14.43 ± 2.92 mmHg (P = 0.11) at 6 months and 1 year, respectively. No patient required oral acetazolamide at the 6-month and 1-year follow-up after surgery. At 1-year, complete and qualified success was seen in 14 eyes each. Six eyes (20%) had an episode of a transient IOP spike, which resolved in 2 weeks, and one eye had hyphema, which resolved by the fourth day. There were no serious complications. CONCLUSIONS: Phacoemulsification with BANG is an effective and safe procedure for reducing the medication burden in patients with primary glaucoma.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。